Amylyx Pharmaceuticals (NASDAQ:AMLX) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) in a research report released on Thursday morning,Zacks reports. The firm issued a strong-buy rating on the stock. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.35) EPS and Q4 2027 earnings at ($0.32) EPS.

AMLX has been the topic of several other reports. Guggenheim upped their price target on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a “buy” rating in a research note on Thursday, August 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Tuesday. Stifel Nicolaus set a $45.00 price objective on shares of Amylyx Pharmaceuticals in a report on Thursday. Mizuho boosted their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, August 18th. Finally, Citigroup increased their target price on shares of Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Amylyx Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $44.14.

Amylyx Pharmaceuticals Stock Up 6.8%

Shares of Amylyx Pharmaceuticals stock traded up $1.88 on Thursday, hitting $29.50. The stock had a trading volume of 1,860,529 shares, compared to its average volume of 1,324,934. The stock has a market cap of $3.29 billion, a price-to-earnings ratio of -20.49 and a beta of -0.09. Amylyx Pharmaceuticals has a twelve month low of $10.83 and a twelve month high of $41.14. The business’s 50 day moving average is $30.00 and its two-hundred day moving average is $20.41.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38). As a group, equities analysts predict that Amylyx Pharmaceuticals will post -1.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director M Jr sold 30,000 shares of the firm’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $27.70, for a total value of $831,000.00. Following the transaction, the director owned 782,881 shares in the company, valued at approximately $21,685,803.70. This trade represents a 3.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gina Mazzariello sold 9,536 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $32.46, for a total value of $309,538.56. Following the completion of the transaction, the insider owned 190,838 shares in the company, valued at $6,194,601.48. The trade was a 4.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 60,374 shares of company stock valued at $1,815,257. Company insiders own 10.90% of the company’s stock.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in shares of Amylyx Pharmaceuticals by 163.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,139 shares of the company’s stock worth $33,000 after acquiring an additional 706 shares during the period. ProShare Advisors LLC increased its stake in Amylyx Pharmaceuticals by 10.7% in the third quarter. ProShare Advisors LLC now owns 17,360 shares of the company’s stock valued at $505,000 after acquiring an additional 1,675 shares during the last quarter. Arizona State Retirement System raised its position in Amylyx Pharmaceuticals by 9.5% during the second quarter. Arizona State Retirement System now owns 19,825 shares of the company’s stock valued at $356,000 after purchasing an additional 1,726 shares in the last quarter. KBC Group NV acquired a new position in Amylyx Pharmaceuticals during the first quarter valued at approximately $26,000. Finally, State of Wyoming acquired a new position in Amylyx Pharmaceuticals during the second quarter valued at approximately $40,000. 95.84% of the stock is owned by institutional investors.

Key Amylyx Pharmaceuticals News

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $55 price target, while forecasting quarterly losses to narrow from $0.38 per share in Q1 2027 to $0.32 in Q4 2027. The rating and target may support investor optimism. Analyst estimates and rating
• Neutral Sentiment: Amylyx reported a Q3 2026 loss of $0.38 per share, matching the consensus estimate. The in-line result was not a positive earnings surprise. Third-quarter financial results
• Neutral Sentiment: The company’s Q3 2026 earnings-call transcript was published, but the provided coverage does not detail additional announcements or outlook changes from the call. Q3 2026 earnings-call transcript

About Amylyx Pharmaceuticals